Analysis and therapy of age-dependent proteostasis failure in neurodegeneration
神经退行性变中年龄依赖性蛋白质稳态失败的分析和治疗
基本信息
- 批准号:10082413
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAmyloidAmyloid beta-42Amyotrophic Lateral SclerosisBindingBiological AssayBrainCaenorhabditis elegansCell Culture TechniquesCellsChemical AgentsChemistryChronicCombined Modality TherapyComplexComputer SimulationComputer softwareCraniocerebral TraumaDataDementiaDevelopmentDiagnosisDiseaseDisease modelDockingDrug DesignDrug ScreeningDrug TargetingElderlyEnvironmental Risk FactorExperimental DesignsExposure toFailureFree EnergyGeneticHeart DiseasesHippocampus (Brain)HumanHuntington DiseaseHypertensionImpairmentIndividualKnowledgeLeadLearningLibrariesLinkMass Spectrum AnalysisMechanicsMediatingModelingMolecularMutateNerve DegenerationNeurodegenerative DisordersNeuronsNeuropathyOxidation-ReductionOxidative StressOxidesParkinson DiseasePathologyPatientsPeptidesPharmaceutical PreparationsPharmacologyPhosphorylated PeptidePost-Translational Protein ProcessingProcessPropertyProtective AgentsProteinsProteomicsProtocols documentationPsyche structureRNA InterferenceRare DiseasesReagentResearch ProposalsResistanceRiskRoleSamplingSignal PathwaySiteSubstantia nigra structureTestingTherapeutic AgentsTissue BanksTissue SampleTissuesTrypsinVeteransactive dutyage relatedalpha synucleinbasebrain cellcohesioncrosslinkdesigndrug candidatedrug efficacyeffective therapyexperiencefirst-in-humangenome-widehigh riskhuman old age (65+)human tissuein silicoin vivoin vivo evaluationinhibitor/antagonistinsightknock-downnovelnovel therapeuticspreventprotective effectprotein aggregationprotein protein interactionproteostasisquantumscreeningsimulationsmall hairpin RNAtau Proteinstherapeutically effectivetool
项目摘要
The previous period of Merit support allowed us to develop novel protocols for immuno-affinity isolation and
characterization of very pure protein aggregates. We began with C. elegans models of neurodegenerative
diseases, and then applied the same protocols to purify Aβ42- and tau-containing aggregates from affected
hippocampal tissue of Alzheimer's patients, seeking aggregate proteins that differentiate them from age-matched
controls. We now propose to apply our experience with these models to develop novel therapeutic agents that
might delay, prevent, or even reverse Alzheimer's and Parkinson's pathology, through the following Aims:
Aim 1. We have access through Dr. Sue Griffin, our collaborator, to a tissue bank of tissue samples from
Alzheimer's Disease (caudal hippocampus) and Parkinson's Disease (substantia nigra), from which we will
isolate aggregates by immuno-affinity for Aβ42, tau and α-synuclein. We propose to cross-link these aggregates,
thoroughly digest them with trypsin, and identify cross-linked peptide pairs that will reveal the protein-protein
interactions that mediated their conglomeration. We will use state-of-the-art “click chemistry” reagents to create,
tag and recover cross-link sites, and Xlink Identifier software to analyze mass-spectrometry data. To visualize,
integrate and interpret the protein-protein interactions thus revealed, we will create protein-interaction networks
and analyze them with tools adapted to the nonfunctional interactions that predominate in protein aggregation.
Aim 2. Proteomics data from Aim 1 will define critical protein-protein interactions within aggregates containing
tau, Aβ42 or α-synuclein, which are highly enriched in Alzheimer or Parkinson brain samples. These protein-
protein interactions will be ranked on the basis of their predicted propensity (by ΔG estimation) and stability (by
molecular-dynamic simulations). The top 10 protein interfaces from each pulldown will then serve as targets for
in silico screening of drug libraries developed to disrupt protein-protein interactions. Such libraries, constructed
in diverse ways, include many `PPII' drugs designed to block specific protein-pair interactions, but which have
frequently found applications beyond their original targets. For each target, we will perform initial screens of
PPII-library drugs in silico, from which the top candidates will be retested in molecular-dynamic simulations.
Aim 3. The drugs predicted in silico to most effectively disrupt key protein interactions (Aim 2) will be tested in
vivo for reduction of aggregate formation―first in human neuronal-cell cultures expressing APPSwe (forming
amyloid aggregates) or split-GFP::tau (fluorescing upon tau oligomerization). For drugs that are protective in
either assay, tests will also be conducted in C. elegans aggregation models expressing Aβ42, tau, or α-synuclein.
Biotinylated versions of 4–6 top candidates will be assessed for activity, and active biotinylated drugs will be
used to pull down proteins to which the drug attaches. This will be done initially in C. elegans, using an in-house
`genomewide' RNAi-knockdown library, and will then be cross-checked by introducing shRNA constructs into
cultured neuronal cells. Targets producing maximal protection will then be tested to ask whether drug efficacy
is partially redundant with RNAi knockdown, as expected for a target that mediates the drug's protective effects.
By discovery of novel drugs designed specifically to reduce aggregation, we expect to find far more effective
therapeutic and preventative agents than the limited drugs currently available. Based on our observations that
many aggregate components are shared among diverse neurodegenerative-disease models, at least some of these
drugs may also prove effective against a variety of other neurodegenerative diseases including orphan diseases.
Merit的前期支持使我们能够开发新的免疫亲和分离方案,
非常纯的蛋白质聚集体的表征。我们从C开始。神经退行性疾病的elegans模型
疾病,然后应用相同的协议,以纯化Aβ42-和tau含有聚集体从受影响的
阿尔茨海默病患者的海马组织,寻找聚集蛋白,将其与年龄匹配的
对照我们现在建议应用我们在这些模型上的经验来开发新的治疗药物,
可能会延迟,预防,甚至逆转阿尔茨海默氏症和帕金森氏症的病理,通过以下目的:
目标1.我们通过我们的合作者苏·格里芬博士,进入了一个组织库,
阿尔茨海默氏病(尾海马)和帕金森氏病(黑质),我们将从
通过对Aβ42、tau和α-突触核蛋白免疫亲和性分离聚集体。我们建议将这些聚合物交联,
用胰蛋白酶彻底消化它们,并鉴定将揭示蛋白质-蛋白质的交联肽对
相互作用,介导了他们的聚集。我们将使用最先进的“点击化学”试剂来创造,
标记和恢复交联位点,以及Xlink Identifier软件来分析质谱数据。为了形象化,
整合并解释由此揭示的蛋白质相互作用,我们将创建蛋白质相互作用网络
并使用适用于在蛋白质聚集中占主导地位的非功能性相互作用的工具来分析它们。
目标二。来自Aim 1的蛋白质组学数据将定义聚集体内的关键蛋白质-蛋白质相互作用,
tau、Aβ42或α-突触核蛋白,其在阿尔茨海默病或帕金森病脑样品中高度富集。这些蛋白质-
蛋白质相互作用将根据其预测倾向(通过ΔG估计)和稳定性(通过
分子动力学模拟)。然后,来自每个下拉的前10个蛋白质界面将作为靶点,
对开发用于破坏蛋白质-蛋白质相互作用的药物文库进行计算机筛选。这样的图书馆,
包括许多旨在阻断特定蛋白质对相互作用的“PPII”药物,但这些药物
经常发现超出其最初目标的应用。对于每个目标,我们将执行初始屏幕,
PPII库药物在计算机上,从其中的顶级候选人将在分子动力学模拟重新测试。
目标3。计算机模拟预测的最有效破坏关键蛋白质相互作用的药物(Aim 2)将在
体内用于减少聚集体形成-首先在表达APPSwe的人类神经元细胞培养物中(形成
淀粉样蛋白聚集体)或分裂-GFP::tau(在tau寡聚化后发荧光)。对于保护性药物,
无论是哪种测定,检测也将在C中进行。elegans聚集模型表达Aβ42、tau或α-突触核蛋白。
将评估4-6种顶级候选物的生物素化形式的活性,并将评估活性生物素化药物的活性。
用来拉下药物附着的蛋白质。这将首先在C中完成。elegans,使用内部
“全基因组”RNAi敲低文库,然后通过将shRNA构建体引入到
培养的神经细胞。然后将测试产生最大保护的靶点,以询问药物疗效是否
与RNAi敲除部分冗余,正如对介导药物保护作用的靶点所预期的那样。
通过发现专门用于减少聚集的新药,我们希望找到更有效的药物,
治疗和预防剂比目前可用的有限药物。根据我们的观察,
许多聚集成分在不同的神经退行性疾病模型中是共享的,至少其中一些是
药物也可证明对多种其它神经变性疾病包括孤儿病有效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Joseph Shmookler Reis其他文献
Robert Joseph Shmookler Reis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Joseph Shmookler Reis', 18)}}的其他基金
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8971964 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8803314 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and therapy of age-dependent proteostasis failure in neurodegeneration
神经退行性变中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
10474260 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8443076 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Analysis and Therapy of Age-Dependent Proteostasis Failure in Neurodegeneration
神经变性中年龄依赖性蛋白质稳态失败的分析和治疗
- 批准号:
8666527 - 财政年份:2013
- 资助金额:
-- - 项目类别:
GENES AFFECTING METABOLISM AND LONGEVITY IN C. ELEGANS
影响线虫新陈代谢和寿命的基因
- 批准号:
7388808 - 财政年份:2007
- 资助金额:
-- - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
-- - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuing Grant